These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15098345)

  • 1. [Treatment of Parkinson disease in patients with surgical problems].
    Sobolewski P
    Neurol Neurochir Pol; 2003; 37 Suppl 5():183-8. PubMed ID: 15098345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 3. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Limits of conventional oral and transdermal medication in Parkinson's disease].
    García-Ruiz PJ; Luquin MR
    Rev Neurol; 2012; 55 Suppl 1():S3-6. PubMed ID: 23169231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
    Dzudza M; Dzudza D
    Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
    Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
    Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of Parkinson's disease.
    Münchau A; Bhatia KP
    Postgrad Med J; 2000 Oct; 76(900):602-10. PubMed ID: 11009573
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mexidant increases the effectiveness of levadopa treatment of Parkinson's disease].
    Fedorova TN; Bagyeva GKh; Dobrotvorskaia IS; Stepanova MS; Polevaia EV; Ivanova-Smolenskaia IA; Illarioshkin SN
    Eksp Klin Farmakol; 2012; 75(6):23-6. PubMed ID: 22891437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous levodopa infusion is better—for now.
    Nutt JG
    Mov Disord; 2015 Apr; 30(4):443-5. PubMed ID: 25757898
    [No Abstract]   [Full Text] [Related]  

  • 13. Updates in the medical management of Parkinson disease.
    Fernandez HH
    Cleve Clin J Med; 2012 Jan; 79(1):28-35. PubMed ID: 22219231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
    Djamshidian A; Poewe W
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B; Mateo D; Giménez-Roldán S
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug management of Parkinson's disease.
    Kishore A; Snow BJ
    Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease: drug therapy.
    Oertel WH; Quinn NP
    Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.